Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise. 1981

V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger

In a total of 18 patients, 7 females and 11 male patients with ages ranging from 23 to 70 years (mean: 45.5 +/- 14.5) diagnostic His bundle studies incorporating programmed atrial and ventricular pacing for the induction of tachycardias was performed before and after betablockade with the cardioselective betablocking agent atenolol, in a dose of 5 mg given iv. over 3 to 5 minutes. In 7 patients the pacing procedure could be repeated following ergometric exercise in order to evaluate the influence of a raised sympathetic tone on the conditions initiating paroxysmal tachycardias. At rest, atenolol prevented the pacing induced tachycardias (20 dysrhythmias in 18 patients) in 3/5 individuals with Wolff-Parkinson-White (WPW)-syndrome, in 4/6 cases with atrial tachycardias, in 4/6 patients presenting atrial flutter, in 2/2 cases developing AV-nodal tachycardias and in 1/1 individual with ventricular tachycardia. Thus, in 13 out of 19 (68%) supraventricular dysrhythmias patients benefitted from atenolol by preventing or controlling the tachycardia. Ergometric exercise changed the tachycardia or echo zone in 5/8 arrhythmias after betablockade when compared to the controls before administration of atenolol (3/5 improvement by narrowing of the tach- or echo zone, 1/5 prevention of tachycardia, 1/5 impairment due to widening of the tachycardia zone). Considering only the prevention of tachycardias, the antiarrhythmic potency of atenolol was improved in one patient with pacing induced flutter and impaired in one individual with a WPW syndrome, by ergometric exercise. These results suggest that atenolol seems to provide a good antiarrhythmic action, especially in supraventricular tachycardias, and that an increased sympathetic tone during exercise may modify the antidysrhythmic strength of betablockade.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D012146 Rest Freedom from activity. Rests
D002304 Cardiac Pacing, Artificial Regulation of the rate of contraction of the heart muscles by an artificial pacemaker. Pacing, Cardiac, Artificial,Artificial Cardiac Pacing,Artificial Cardiac Pacings,Cardiac Pacings, Artificial,Pacing, Artificial Cardiac,Pacings, Artificial Cardiac
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
February 1992, The American journal of cardiology,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
January 1977, Postgraduate medical journal,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
January 1988, Zeitschrift fur Kardiologie,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
June 1990, Cardiovascular drugs and therapy,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
July 1997, Cardiovascular drugs and therapy,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
October 1981, International journal of clinical pharmacology, therapy, and toxicology,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
August 1988, The American journal of cardiology,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
July 1993, Journal of cardiovascular pharmacology,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
March 1995, The American journal of cardiology,
V Hombach, and V Braun, and H W Höpp, and D Gil-Sanchez, and D W Behrenbeck, and M Tauchert, and H H Hilger
January 1989, European journal of clinical pharmacology,
Copied contents to your clipboard!